TD Asset Management Inc Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY

TD Asset Management Inc reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 269,101 shares of the biopharmaceutical company’s stock after selling 43,416 shares during the period. TD Asset Management Inc’s holdings in Alnylam Pharmaceuticals were worth $107,008,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $29,000. Ameriflex Group Inc. purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $36,000. Newbridge Financial Services Group Inc. acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Eastern Bank acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $42,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,740 shares of company stock valued at $2,420,214 over the last ninety days. Insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALNY shares. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target on the stock. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Finally, Jefferies Financial Group restated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $303.64 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $283.10 and a twelve month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a 50-day moving average of $308.18 and a 200-day moving average of $349.69. The firm has a market cap of $40.54 billion, a price-to-earnings ratio of 82.96 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the firm posted ($0.44) EPS. The business’s revenue for the quarter was up 96.4% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.